Roxadustat Market Size Projected To Reach 9.15 Billion By 2034 With A Cagr Of 7.3%

"We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.

What Is the Projected Growth of the Roxadustat Market?
Over the past few years, the Roxadustat market has exhibited robust growth. It is projected to rise from $6.44 billion in 2024 to $6.92 billion in 2025, with a compound annual growth rate (CAGR) of 7.5%. Factors such as regulatory green signals in key markets, positive outcomes from clinical trials, a greater incidence of chronic kidney disease, heightened awareness about anemia management, and government backing for anemia therapies have conveyed this increase during the historical period.

Strong expansion in the Roxadustat market size is anticipated in the upcoming years, reaching a valuation of $9.16 billion in 2029, with a compound annual growth rate (CAGR) of 7.3%. Factors contributing to the growth during this forecast period include continued studies around new indications, a rise in healthcare spendings, need for anemia treatments that don't require injections, wider reimbursement policies, and an increase in the elderly population. The observing trends throughout the forecast period encompass a move towards oral treatments for anemia, rising competitions from other therapeutic methods, the broadening of licensing agreements, increasing funding in research on hypoxia-inducible factors, and a shift towards treatments that are more focused on the patient.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21280

What Are the Different Roxadustat Market Segments?
The roxadustat market covered in this report is segmented -

1) By Type: 20mg, 50mg
2) By Product Formulation: Oral Tablets
3) By Distribution Channel: Hospitals, Specialty Pharmacies, Dialysis Centers
4) By End-User Application: Chronic Kidney Disease-Associated Anemia, Other Anemia Conditions

Subsegments:
1) By 20mg: Oral Tablets, Injectable Formulations
2) By 50mg: Oral Tablets, Injectable Formulations

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21280&type=smp

What Are the Primary Drivers Shaping the Roxadustat Market?
The escalating figures of individuals afflicted by chronic kidney disease (CKD) are projected to drive the expansion of the Roxadustat market. CKD is a long-term ailment that results in a step-by-step loss of kidney function, which, without treatment, can escalate into kidney failure. The global increase in CKD patients can be attributed to numerous factors such as an aging population, rising diabetes and hypertension rates, and poor lifestyle choices. Roxadustat acts as a management tool for CKD, as it stimulates the production of erythropoietin, elevating the production of red blood cells and addressing the often conjoined issue of anemia. This ultimately improves kidney function and enhances quality of life for patients. To illustrate, as per a December 2024 report from the Australian Institute of Health and Welfare (AIHW), an Australia-based government agency, there was a moderate annual increase in mortality rates due to CKD, with a 4.2% rise documented in 2021 and a 6.2% increase in 2022. This trend of escalating CKD cases globally is hence fueling the expansion of the Roxadustat market.

Which Companies Are Leading in the Roxadustat Market?
Major companies operating in the roxadustat market are AstraZeneca PLC, Viatris Inc., Astellas Pharma Inc., Dr. Reddy's Laboratories Ltd., Hetero Drugs Limited, Akebia Therapeutics Inc., Metrochem API Private Limited, FibroGen Inc., AMI Lifesciences, Lee Pharma Ltd., Faran Shimi Pharmaceutical Company, Maithri Drugs Pvt. Ltd., Clearsynth Labs Ltd., Bal Pharma, HEMA Pharmaceuticals Pvt. Ltd., Zhejiang Hengkang Pharmaceutical Co. Ltd., Kimia Biosciences Pvt. Ltd., Lewens Labs Pvt. Ltd., Hangzhou Longshine Bio-Tech Co. Ltd., GLR Innovations, Suzhou Biosyntech Co. Ltd., Shanvr Life Sciences Pvt. Ltd.

What Are the Major Trends Shaping the Roxadustat Market?
In the Roxadustat market, key players are pursuing reimbursement via the high-tech drugs scheme. This strategy aims to increase patient availability by lessening financial constraints, consequently boosting market adoption and showcasing the cost-efficiency of their pioneering therapies. Specifically controlled in Ireland, this high-tech drugs scheme offers reimbursement for the provision of costly, highly specific medications generally prescribed in hospital situations. For example, Astellas Pharma Company Ltd., an American pharmaceutical company, disclosed in September 2022 that their product EVRENZO (Roxadustat), had earned reimbursement under Ireland's High-Tech Drugs Scheme. Roxadustat is the premier drug of its kind, an orally taken hypoxia-inducible factor prolyl hydroxylase (HIF PH) inhibitor, that is both licensed and reimbursed in Ireland. It has proven effective in reaching and upholding designated hemoglobin quantities (10-12g/dL) in patients suffering from symptomatic anemia of CKD, irrespective of dialysis condition and former ESA treatments.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/roxadustat-global-market-report

What Are the Top Revenue-Generating Geographies in the Roxadustat Market?
North America was the largest region in the Roxadustat market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the roxadustat market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Roxadustat Market?
2. What is the CAGR expected in the Roxadustat Market?
3. What Are the Key Innovations Transforming the Roxadustat Industry?
4. Which Region Is Leading the Roxadustat Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company provides in-depth research and insights through a vast collection of 15,000+ reports spanning 27 industries and over 60 geographies. Backed by 1,500,000 datasets, extensive secondary research, and expert insights from industry leaders, we equip you with the knowledge needed to stay ahead in the market.

Our flagship offering, the Global Market Model, is a leading market intelligence platform that delivers comprehensive and up-to-date forecasts to support strategic decision-making.

This release was published on openPR.